• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

The platform


What was the EPAD platform?

The EPAD PoC platform was developed as an open-ended resource for adaptive, multi-arm drug development proof-of-concept studies for early and accurate decisions on the ongoing development of drug candidates, drug combinations, or other interventions for the secondary prevention of Alzheimer’s dementia.


How did EPAD work?

The platform was designed with a world-leading consortium of 39 partners to efficiently deliver early, accurate results. EPAD planned to study new drugs in a well-designed Phase II PoC trial with clinical endpoints prior to Phase III, utilising the power of adaptive design and Bayesian statistics.

The platform was supported by three key strategies: the EPAD register, the cohort and trial.


The participants


What patient populations were enrolled into the EPAD longitudinal cohort?

Diagnosis: The Longitudinal Cohort Study (LCS) included subjects with evidence for Alzheimer’s disease pathology.

Severity: The study population spaned the full continuum from no symptoms (i.e., preclinical Alzheimer’s disease) through the late stages of prodromal Alzheimer’s dementia or MCI due to Alzheimer’s dementia, but included nobody who already met criteria for a diagnosis of dementia.

Biological fingerprint: The requirement for Alzheimer’s disease pathology entails the use of CSF. The LCS also included some subjects who had some evidence for Alzheimer’s disease pathology but who did not meet standardised cut-offs for amyloid positivity (i.e. who are in a “grey zone” pathologically) and some control subjects who were amyloid negative.

Genetics: The LCS population comprised sporadic and not dominantly inherited Alzheimer’s disease. The population selection process involved some enrichment for ApoE4+ genotype, but the full population included subjects who were both ApoE4+ and -.


What data were collected from research participants?

Cognitive: A cognitive battery that is appropriate for the full spectrum of cognitive status in the LCS population and that is sensitive to change over time was developed and wwas used to follow LCS subjects at regular intervals. The availability of such longitudinal run-in data for subjects who are eligible for the PoC trial was a key advantage of EPAD, as it provided individual data on the rate of decline that can served as a baseline set of assessments and increase the study’s power to detect change due to treatment.

Behavioural: Assessments of depression, anxiety, and sleep were proposed.

Functional: A functional assessment was included. At this time, the Amsterdam IADL Scale was being considered, and actigraphy was included.

Imaging: MRI, including fMRI, was included and other types added.

Tissue: See above.

  • CSF
  • Plasma
  • DNA

A full list of all outcome measures is available at the ClinicalTrials.gov EPAD LCS study record.


Where were these research participants seen and followed?

The EPAD project included more than 40 Trial Delivery Centres (TDC) that conducted the LCS. These centres were highly experienced and underwent further training for standardisation as part of EPAD.


How often research participants were seen?

Research participants were followed up every 6 months during the first year and annually thereafter. The frequency of follow-up in the PoC was be determined during the protocol development process according to the intervention owners requirements.


Will their data be available?

All LCS data are available in accordance with the access rights provided for in the EPAD Project Agreement.


The study design


What were the core elements of the EPAD PoC study design?

Key features of the PoC study design were:

  • Use of a cognitive measure as the primary endpoint.
  • Frequent interim analyses for success and futility.
  • Advancement of interventions that achieve an effect on an intermediate phenotype or biomarker of target engagement to the clinical stage of the study (note: interventions that have already demonstrated target engagement may bypass this step).
  • Bayesian statistical models used to adapt on the cognitive measure to achieve faster randomisation to doses/drugs that appear more effective overall or in specific subpopulations.
  • Efficient use of the accruing data, e.g., by utilizing all assessments within a longitudinal model.
  • Randomisation to drug or placebo for each intervention, with analysis using combined data from all placebo subjects to increase the power of the analyses.


Which elements were fixed?

A standard set of efficacy and safety measures were assessed in all subjects.


Which elements were adaptive?

The key adaptive features were adaptive randomisation of subjects and the ability to discontinue a drug treatment for futility or evidence for early success in the PoC, i.e. efficacy data indicating readiness for Phase III. Adaptive randomisation could be used to preferentially assign subjects to doses of a drug that appeared more efficacious at an interim analysis. It was also possible that subpopulations of subjects, defined by clinical, biomarker, or genetic criteria, could be preferentially randomised to a specific drug based on evidence for greater efficacy of that drug in that subpopulation at an interim analysis. Other adaptations could be considered if warranted by the needs of a drug or drug owner.


How amendments were handled?

Essentially, the addition of each new drug to the PoC entailed an appendix in which the specific treatment parameters and assessments were described. Such appendices or amendments were developed jointly by the EPAD Clinical Development Executive Committee – the group responsible for overall study design – and the intervention owner.


What was the analysis plan for these data?

The primary analyses utilised Bayesian statistics. This approach was more powerful for determining the probability of success of a given drug at multiple interim analyses and therefore led to faster decision-making.


The interventions


Which therapies were considered?

The Clinical Candidate Selection Committee (CCSC) evaluated all nominated compounds or other interventions. To be eligible, interventions had scientific support for potential efficacy in the prevention of Alzheimer’s dementia or delay in progression of symptoms, and adequate preclinical and clinical safety to support advancement to Phase II.

Novel small molecules, repurposed molecules, biologics, vaccines and combinations of these were considered.


How interventions were selected?

All interventions selected for potential use in the PoC were evaluated on the following criteria:

  • Scientific rationale
  • Pharmacokinetics
  • Pharmacology requirements
  • Safety
  • Plans for full development/regulatory issues
  • Develop-ability/CMC Quality guidelines
  • Biomarkers


What data were required to have a therapy considered?

Any intervention that was be considered ready for PoC in development for Alzheimer’s dementia had already the data required to be eligible for inclusion.


How was a therapy selected for entry into the study and by whom?

We worked closely with the intervention owner, in advance of study initiation, to ensure that the timing of inclusion of the drug worked. We ensured that interventions were added to the study on the expected timeline.

How was safety information handled so that the owner of the therapy remained compliant?

A single academic entity (University of Edinburgh) was the sponsor of the EPAD PoC trial and took full responsibility for ensuring compliance across the project.


How was bias or conflict of interest controlled for in the selection of therapies?

Members of the CCSC were required to sign non-disclosure agreements before reviewing nominations. The committee  included novody with potential conflicts of interest.


What about potential synergistic combinations?

Testing combinations was a specific goal of EPAD and it was expected that combinations of therapies were proposed for inclusion. The same criteria was used for selecting combinations as for selecting single therapies.


How proprietary information were protected?

The EPAD Project Agreement included confidentiality provisions that were also applicable to employees of EPAD members. However, if requested by the intervention owner, all CCSC members signed confidentiality agreements before reviewing confidential information. Confidential information were submitted and maintained using secure processes with limited access. Submission of a full nomination only occurred after informal discussion with the CCSC to ensure that an intervention had all data sufficient for evaluation.


 

Share this page
FacebookTwitterLinkedInGoogle+
Latest News
  • Analysis of multiple steroids in saliva in the EPAD study
    2023-03-02
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
    2023-01-16
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
    2022-12-09
  • Bruno Steinkraus
    Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
    2022-11-25
  • New paper defining and discussing the substantial assets of the EPAD project is out!
    2022-11-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

📢@imi_epnd has launched its Cohort Catalogue, a central, open & accessible repository for researchers to discover studies & search metadata. Currently 67 research cohorts from 17 countries across Europe including @IMI_EPAD-VUmc participants ⬇️ eurekalert.org/news-releases/… twitter.com/imi_epnd/statu…

reply retweet favorite
9:56 am · 2023-03-14
Twitter
EPAD
EPAD
@IMI_EPAD

NEW paper published in @MetabolitesMDPI using LC-MS/MS method to determine salivary steroids using @IMI_EPAD samples. Congratulations @GregorySarah @zinghomer @guider50 @scottgdenham👏 @EdMassSpecCore @IMI2_NEURONET @IHIEurope #mdpimetabolites mdpi.com/2133518

reply retweet favorite
12:55 pm · 2023-03-02
Twitter
EPAD
EPAD
@IMI_EPAD

"There is a growing consensus that individual research results that are potentially relevant should be reported to research participants” & “Our work was positively received by the EPAD partners, and formed the basis for the set-up & the conduct of the study,” said Eline Bunnik

reply retweet favorite
10:32 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the @IHIEurope newsletter including a spotlight on IMI results from projects on diabetes @HypoResolve and #Alzheimer’s disease @IMI_EPAD @IMI_AMYPAD ⬇️ Read it: bit.ly/3jeaxdM twitter.com/IHIEurope/stat…

reply retweet favorite
10:30 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

17 centres have contributed to the @IMI_AMYPAD Prognostic Study across 11 Parent Cohorts including @IMI_EPAD. Have a look on the latest AMYPAD paper published in @FrontNeurol ⬇️ twitter.com/IMI_AMYPAD/sta…

reply retweet favorite
8:19 am · 2023-01-30
Workstream Progress
Workstream 120%
Workstream 232%
Workstream 310%
Workstream 446%
Contact us

Submitclear

Recent Posts
  • Analysis of multiple steroids in saliva in the EPAD study
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
  • Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
  • New paper defining and discussing the substantial assets of the EPAD project is out!
Recent Comments
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench on The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
  • ADDI celebrates one year of achievements – Neuronet on ADDI celebrates one year of achievements
  • EPAD dataset is now available on the Alzheimer’s Disease Workbench on The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
  • The final EPAD dataset is now available to the entire research community on The final EPAD dataset is now available to the entire research community
  • The ERC has awarded an ERC grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease – Neuronet on New ERC starting grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease
Archives
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
Categories
  • EPAD Academy
  • News
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT